

November 2008 PBAC OUTCOMES - Deferrals

DRUG AND FORM	DRUG USE AND TYPE	LISTING REQUESTED BY SPONSOR	PBAC OUTCOME AND COMMENT
Dornase alfa, solution for inhalation 2.5 mg (2,500 units) in 2.5 mL, (Pulmozyme [®]) Roche Products Pty Ltd Minor submission	Helps manage the respiratory complications of cystic fibrosis	Seeks changes to the current restriction wording to include use in patients aged < 5 years and the inclusion of grandfather clauses.	Deferred to allow further dialogue with the Thoracic Society of Australia and New Zealand (TSANZ) and other stakeholders.
		Sponsor's comments:	The sponsor did not provide any comments.